Onconova Therapeutics Inc. [ONTX] gain 149.03% so far this year. What now?

Onconova Therapeutics Inc. [NASDAQ: ONTX] closed the trading session at $1.16 on 02/12/21. The day’s price range saw the stock hit a low of $1.10, while the highest price level was $1.25. The company report on February 11, 2021 that Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.00 per share. The gross proceeds of the offering to the Company are expected to be $25.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Onconova granted the underwriters a thirty-day option to purchase up to an additional 3,750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

The closing of the offering is expected to occur on or about February 16, 2021, subject to the satisfaction of customary closing conditions.

The stocks have a year to date performance of 149.03 percent and weekly performance of 33.96 percent. The stock has been moved at 14.85 percent over the last six months. The stock has performed 70.59 percent around the most recent 30 days and changed 329.31 percent over the most recent 3-months.

If compared to the average trading volume of 37.93M shares, ONTX reached to a volume of 33640368 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Onconova Therapeutics Inc. [ONTX]:

H.C. Wainwright have made an estimate for Onconova Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 01, 2018. The new note on the price target was released on January 17, 2018, representing the official price target for Onconova Therapeutics Inc. stock. Previously, the target price had yet another raise to $6, while H.C. Wainwright analysts kept a Buy rating on ONTX stock.

The Average True Range (ATR) for Onconova Therapeutics Inc. is set at 0.16, with the Price to Sales ratio for ONTX stock in the period of the last 12 months amounting to 1198.98. The Price to Book ratio for the last quarter was 16.57, with the Price to Cash per share for the same quarter was set at 0.12.

ONTX stock trade performance evaluation

Onconova Therapeutics Inc. [ONTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.96. With this latest performance, ONTX shares gained by 70.59% in over the last four-week period, additionally plugging by 14.85% over the last 6 months – not to mention a rise of 110.91% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONTX stock in for the last two-week period is set at 73.99, with the RSI for the last a single of trading hit 76.68, and the three-weeks RSI is set at 71.96 for Onconova Therapeutics Inc. [ONTX]. The present Moving Average for the last 50 days of trading for this stock 0.6190, while it was recorded at 1.1400 for the last single week of trading, and 0.5225 for the last 200 days.

Onconova Therapeutics Inc. [ONTX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Onconova Therapeutics Inc. [ONTX] shares currently have an operating margin of -994.00. Onconova Therapeutics Inc.’s Net Margin is presently recorded at -985.02.

Return on Total Capital for ONTX is now -255.87, given the latest momentum, and Return on Invested Capital for the company is -253.56. Return on Equity for this stock declined to -253.56, with Return on Assets sitting at -103.39.

Reflecting on the efficiency of the workforce at the company, Onconova Therapeutics Inc. [ONTX] managed to generate an average of -$1,131,737 per employee. Receivables Turnover for the company is 32.83 with a Total Asset Turnover recorded at a value of 0.10.Onconova Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.

Earnings per share (EPS) analysis for Onconova Therapeutics Inc. [ONTX] stock

With the latest financial reports released by the company, Onconova Therapeutics Inc. posted -0.4/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -60.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONTX.

Onconova Therapeutics Inc. [ONTX]: Insider Ownership positions

There are presently around $17 million, or 10.10% of ONTX stock, in the hands of institutional investors. The top three institutional holders of ONTX stocks are: VANGUARD GROUP INC with ownership of 8,260,810, which is approximately 19.154% of the company’s market cap and around 0.30% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 1,288,206 shares of the stock with an approximate value of $1.49 million in ONTX stocks shares; and PRINCIPAL FINANCIAL GROUP INC, currently with $1.35 million in ONTX stock with ownership of nearly New of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Onconova Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 22 institutional holders increased their position in Onconova Therapeutics Inc. [NASDAQ:ONTX] by around 4,909,075 shares. Additionally, 13 investors decreased positions by around 1,095,406 shares, while 9 investors held positions by with 8,773,073 shares. The mentioned changes placed institutional holdings at 14,777,554 shares, according to the latest SEC report filing. ONTX stock had 13 new institutional investments in for a total of 2,300,760 shares, while 8 institutional investors sold positions of 812,204 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam